On March 23, MSCI Inc (Morgan Stanley Capital International) announced its latest annual Environmental, Social, and Governance (ESG) ratings, with HANSOH PHARMA's ESG rating upgraded to the global highest level of "AAA." Previously, HANSOH PHARMA had maintained an "AA" rating from MSCI ESG for three consecutive years, securing a leading position in China's pharmaceutical industry and ranking among the top global peers. In the current MSCI rating report, HANSOH PHARMA's environmental performance and social value contributions received further recognition, placing the company among the global ESG leaders. Currently, all five key ESG metrics for HANSOH PHARMA—Corporate Governance, Product Safety & Quality, Human Resources Development, Access to Healthcare, and Toxic Emissions & Waste—are rated at the "ESG Leader" level. MSCI is one of the world's authoritative ESG index and rating agencies, and its ratings are widely used as a key reference for international capital market investments. The upgrade from "AA" to the highest "AAA" rating reflects MSCI's strong endorsement of HANSOH PHARMA's commitment to innovation-driven growth, deepened ESG practices, and sustainable business development. It also highlights the company's outstanding performance in corporate governance, scientific research and innovation, product quality, accessible healthcare, talent development, community welfare, sustainable supply chain management, and low-carbon environmental protection. Thanks to its continuous efforts and excellence in the ESG field, HANSOH PHARMA has gained broad recognition from global authoritative ESG rating agencies in recent years. In the latest S&P Global Sustainability Yearbook 2026, HANSOH PHARMA was once again included, with its score in the S&P Global Corporate Sustainability Assessment (CSA) continuing to improve. The company has ranked first in China's pharmaceutical industry for five consecutive years. Additionally, HANSOH PHARMA has been repeatedly listed on CDP's Climate Change and Water Security "B" lists and has received multiple authoritative certifications and honors, including "Forbes China ESG 50," "China Pharmaceutical Listed Companies ESG Competitiveness Ranking," and the "ESG Pioneer Award." Fulfilling social responsibility is a vital pathway for enterprises to achieve long-term sustainability, create lasting value, and realize win-win outcomes for all stakeholders. HANSOH PHARMA remains committed to actively supporting the United Nations Sustainable Development Goals, continuously implementing advanced ESG practices, and contributing further to the long-term development of the global economy, environment, and society.